Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: Evaluation of 177Lu and comparison of its efficacy with that of 90Y and residualizing 131I

Journal of Nuclear Medicine

Volumn 42, Issue 6, 2001, Pages 967-974

  Stein, R ^a   Govindan, S V ^a   Chen, S ^a   Reed, L ^a   Richel, H ^a   Griffiths, G L ^a   Hansen, H J ^a   Goldenberg, D M ^a  

^a GARDEN STATE CANCER CENTER   (United States)

Author keywords

131I; 177Lu; 90Y; Radioimmunotherapy; Residualizing labels

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; IODINE 131; LUTETIUM; LUTETIUM 177; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY RS7; UNCLASSIFIED DRUG; YTTRIUM; YTTRIUM 90;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; ISOTOPE LABELING; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; GLYCOPROTEINS; HETEROCYCLIC COMPOUNDS, 1-RING; HUMANS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; LUTETIUM; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; RADIOIMMUNOTHERAPY; RADIOISOTOPES; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; YTTRIUM RADIOISOTOPES;

EID: 0034974619     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Characterization of cluster 13: The epithelial/carcinoma antigen recognized by MAb RS7
2. Specificity and properties of MAb RS7-3G11 and the antigen defined by this pancarcinoma monoclonal antibody
3. 131I-labeled monoclonal antibody RS7-3G11
4. Effects of radiolabeling monoclonal antibodies with a residualizing iodine radiolabel on the accretion of radioisotope in tumors
5. Advantage of a residualizing iodine radiolabel for radioimmunotherapy of xenografts of human non-small cell carcinoma of the lung
6. Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft
7. Murine monoclonal antibodies raised against human non-small cell carcinoma of the lung: Specificity and tumor targeting
8. Intracellular catabolism of radiolabeled anti-μ antibodies by malignant B-cells
9. Glycoprotein catabolism in rat liver: Lysosomal digestion of iodinated asialo-fetuin
10. Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells
11. Metabolism of indium-111-labeled murine monoclonal antibody in tumor and normal tissue of the athymic mouse
12. The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: A comparison of nine radiolabels
13. Improving the tumor retention of radioiodinated antibody: Arylcarbohydrate adducts
14. Tumor specific anti-epidermal growth factor receptor variant 111 monoclonal antibodies: Use of the tyramine-cellobiose radioiodination method enhances cellular retention and uptake in tumor xenografts
15. Radioiodination of internalizing monoclonal antibodies using N-succinimidyl 5-iodo-3-pyridinecarboxylate
16. Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22
17. The advantage of residualizing radiolabels for targeting B-cell lymphomas with a radiolabeled anti-CD22 monoclonal antibody
18. Labeling of monoclonal antibodies with DTPA-appended radioiodinated peptides containing D-amino acids
19. Targeting human cancer xenografts with MAbs labeled using radioiodinated, DTPA-appended, peptides
20. Successful therapy of a human lung cancer xenograft using MAb RS7 labeled with residualizing radioiodine
21. 177lutetium-labeled immunoconjugate
22. Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules
23. 90Yttrium-labeled complementarity-determining-region-grafted monoclonal antibodies for radioimmunotherapy: Radiolabeling and animal biodistribution studies
24. Facile lutetium-177 (Lu-177) labelings of humanized monoclonal antibodies (hMAbs) for radioimmunotherapy (RAIT)
25. Characterization of second-generation monoclonal antibodies against carcinoembryonic antigen
26. Conjugation of antibodies with bifunctional chelating agents: Isothiocyanate and bromoacetamide reagents, methods of analysis, and subsequent addition of metal ions
27. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infinite antigen excess
28. Absorbed fractions for electrons and beta particles in spheres of various sizes
29. Selection of radioimmunoconjugates for therapy of well established or micrometastatic colon carcinoma
30. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations
31. A mouse bone marrow dosimetry model
32. Asymptotically efficient rank invariant test procedures
33. Haematologic effects of radioimmunotherapy in cancer patients
34. Intraperitoneal radioimmunotherapy of ovarian cancer with Lu-177-CC49
35. 177Lu-labeled CC49 murine monoclonal antibody in patients with advanced adenocarcinoma
36. Quantitative 5-minute radiolabeling of DOTA-hMAb conjugates with Y-90 for cancer radioimmunotherapy
37. 177Lu, is most promising for radionuclide therapy of somatostatin receptor-positive tumors
38. 3-octreotate